Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study

Open access

Abstract

Voretigene neparvovec (VN) is the first available gene therapy for patients with biallelic RPE65-mediated inherited retinal dystrophy who have sufficient viable retinal cells. PERCEIVE is an ongoing, post-authorization, prospective, multicenter, registry-based observational study and is the largest study assessing the real-world, long-term safety and effectiveness of VN. Here, we present the outcomes of 103 patients treated with VN according to local prescribing information. The mean (SD) age was 19.5 (10.85) years, 52 (50.5%) were female, and the mean (SD) duration of the follow up was 0.8 (0.64) years (maximum: 2.3 years). Thirty-five patients (34%) experienced ocular treatment-emergent adverse events (TEAEs), most frequently related to chorioretinal atrophy (n = 13 [12.6%]). Eighteen patients (17.5%; 24 eyes [13.1%]) experienced ocular TEAEs of special interest, including intraocular inflammation and/or infection related to the procedure (n = 7). The mean (SD) changes from baseline in full-field light-sensitivity threshold testing (white light) at month 1, month 6, year 1, and year 2 were −16.59 (13.48) dB (51 eyes), −18.24 (14.62) dB (42 eyes), −15.84 (14.10) dB (10 eyes), and −13.67 (22.62) dB (13 eyes), respectively. The change in visual acuity from baseline was not clinically significant. Overall, the outcomes of the PERCEIVE study are consistent with the findings of VN pivotal clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom14010122

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean change from baseline in FST (white light) up to 2 years after VN administration in all patients, patients aged <18 years and those aged ≥18 years. dB, decibel; FST, full-field light-sensitivity threshold testing; n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 127 eyes. Error bars represent SD.
Figure 1 Mean change from baseline in FST (white light) up to 2 years after VN administration in all patients, patients aged <18 years and those aged ≥18 years. dB, decibel; FST, full-field light-sensitivity threshold testing; n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 127 eyes. Error bars represent SD.CC BY · PubMed Central
Figure 2 Mean change from baseline in VA (LogMAR) up to 2 years after receiving VN in all patients, patients aged <18 years, and those aged ≥18 years. VA, visual acuity; LogMAR, logarithm of the minimum angle of resolution; n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 148 eyes. Error bars represent SD.
Figure 2 Mean change from baseline in VA (LogMAR) up to 2 years after receiving VN in all patients, patients aged <18 years, and those aged ≥18 years. VA, visual acuity; LogMAR, logarithm of the minimum angle of resolution; n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 148 eyes. Error bars represent SD.CC BY · PubMed Central
Figure 3 Mean change from baseline in foveal thickness (µm; Heidelberg Spectralis OCT) up to 2 years after VN therapy in all patients, patients aged <18 years, and those aged ≥18 years. n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 117 eyes. Error bars represent SD.
Figure 3 Mean change from baseline in foveal thickness (µm; Heidelberg Spectralis OCT) up to 2 years after VN therapy in all patients, patients aged <18 years, and those aged ≥18 years. n, number of eyes; VN, voretigene neparvovec. Baseline data were available for 117 eyes. Error bars represent SD.CC BY · PubMed Central
Figure 4 Mean change in FST (white light) from baseline in patients with CRAs versus those without CRAs. BL, baseline; dB, decibel; CRA, chorioretinal atrophy; FST, full-field light-sensitivity threshold testing; n, number of eyes. Baseline data are available for 15 eyes with CRAs and 112 eyes without CRAs. Error bars indicate SD.
Figure 4 Mean change in FST (white light) from baseline in patients with CRAs versus those without CRAs. BL, baseline; dB, decibel; CRA, chorioretinal atrophy; FST, full-field light-sensitivity threshold testing; n, number of eyes. Baseline data are available for 15 eyes with CRAs and 112 eyes without CRAs. Error bars indicate SD.CC BY · PubMed Central
Figure 5 Mean change in VA (LogMAR) from baseline in patients with CRAs versus those without CRAs. VA, visual acuity; BL, baseline; CRA, chorioretinal atrophy; LogMAR, logarithm of minimum angle of resolution; n, number of eyes. Baseline data are available for 19 eyes with CRAs and 129 eyes without CRAs. Error bars indicate SD.
Figure 5 Mean change in VA (LogMAR) from baseline in patients with CRAs versus those without CRAs. VA, visual acuity; BL, baseline; CRA, chorioretinal atrophy; LogMAR, logarithm of minimum angle of resolution; n, number of eyes. Baseline data are available for 19 eyes with CRAs and 129 eyes without CRAs. Error bars indicate SD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Isabelle Audo, J.A.S., Barale, P.O., Said, S.M., Devisme, C., Pagot, C., and Chapn, P. (2022, January 21). LIGHT—Observational study on the use of voretigene neparvovec in patients with inherited retinal dystrophy at CHNO des Quinze-Vingts: A 1-year follow-up of a 12-case series. Proceedings of the EURETINA—European Society of Retina Specialists, Hamburg, Germany.

Cited by

See all 83

Metadata

Authors
Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., & Leroy, B. P.
Affiliations
  • University of Oxford (GB)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Novartis (Switzerland) (CH)
  • University of Bonn (DE)
  • Retina International, D02 TW98 Dublin, Ireland; Retina Suisse, 8005 Zürich, Switzerland
  • Novartis (United States) (US)
  • Centre National de la Recherche Scientifique (FR)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Fischer, M. Dominik
Venue
Biomolecules
Publisher
MDPI AG
Published
2024-01-17
Volume
14
Issue
1
Pages
122
ISSN
2218-273X (ISSN-L)
OpenAlex
W4390944289
Cited by
70
References
18
Citations by year
2026: 31 · 2025: 32 · 2024: 7
FWCI
9.53
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
Novartis Pharma AG
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
voretigene neparvovec, gene therapy, real-world safety, long-term effectiveness, chorioretinal atrophy, intraocular inflammation, intraocular infection, visual acuity
MeSH terms
Adult, Female, Humans, Male, Prospective Studies, Registries, Retina, Genetic Therapy, Choroid Diseases, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. https://app.cochat.ai/papers/10.3390/biom14010122
The paper
Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., & Leroy, B. P. (2024). Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules. https://doi.org/10.3390/biom14010122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.